NYSE:PFE - Pfizer Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $42.09 +0.67 (+1.62 %) (As of 08/19/2018 05:27 AM ET)Previous Close$42.09Today's Range$41.47 - $42.1952-Week Range$32.32 - $42.19Volume24.57 million shsAverage Volume22.35 million shsMarket Capitalization$243.65 billionP/E Ratio15.88Dividend Yield3.30%Beta0.96 Company ProfileAnalyst RatingsChartDividend HistoryEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brand names. This segment also engages in the research and development, as well as contract manufacturing activities. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company for the development of Eliquis; Astellas Pharma US, Inc. for developing Xtandi; Merck KGaA for the development of Bavencio; and Neofluidics, LLC to develop a microfluidics-based platform. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Receive PFE News and Ratings via Email Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical SymbolNYSE:PFE CUSIP71708110 Webwww.pfizer.com Phone212-733-2323 Debt Debt-to-Equity Ratio0.41 Current Ratio1.16 Quick Ratio0.91 Price-To-Earnings Trailing P/E Ratio15.88 Forward P/E Ratio14.08 P/E Growth1.98 Sales & Book Value Annual Sales$52.55 billion Price / Sales4.77 Cash Flow$3.8579 per share Price / Cash10.91 Book Value$12.02 per share Price / Book3.50 Profitability EPS (Most Recent Fiscal Year)$2.65 Net Income$21.31 billion Net Margins42.35% Return on Equity25.35% Return on Assets10.29% Miscellaneous Employees90,200 Outstanding Shares5,952,870,000Market Cap$243.65 billion Pfizer (NYSE:PFE) Frequently Asked Questions What is Pfizer's stock symbol? Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE." How often does Pfizer pay dividends? What is the dividend yield for Pfizer? Pfizer announced a quarterly dividend on Thursday, June 28th. Investors of record on Friday, August 3rd will be paid a dividend of $0.34 per share on Tuesday, September 4th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.23%. The ex-dividend date is Thursday, August 2nd. View Pfizer's Dividend History. How will Pfizer's stock buyback program work? Pfizer announced that its board has initiated a stock buyback plan on Tuesday, December 19th 2017, which allows the company to repurchase $10,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Shares repurchase plans are often an indication that the company's board of directors believes its stock is undervalued. How were Pfizer's earnings last quarter? Pfizer Inc. (NYSE:PFE) posted its quarterly earnings data on Tuesday, July, 31st. The biopharmaceutical company reported $0.81 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.74 by $0.07. The biopharmaceutical company earned $13.47 billion during the quarter, compared to the consensus estimate of $13.30 billion. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The firm's quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.67 EPS. View Pfizer's Earnings History. When is Pfizer's next earnings date? Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, October, 30th 2018. View Earnings Estimates for Pfizer. What guidance has Pfizer issued on next quarter's earnings? Pfizer updated its FY18 earnings guidance on Tuesday, July, 31st. The company provided earnings per share guidance of $2.95-3.05 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.95. The company issued revenue guidance of $53-55 billion, compared to the consensus revenue estimate of $54.25 billion. What price target have analysts set for PFE? 20 brokerages have issued 1 year target prices for Pfizer's stock. Their forecasts range from $37.00 to $45.00. On average, they anticipate Pfizer's share price to reach $41.1176 in the next twelve months. This suggests that the stock has a possible downside of 2.3%. View Analyst Price Targets for Pfizer. What is the consensus analysts' recommendation for Pfizer? 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 2 sell ratings, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pfizer. Are investors shorting Pfizer? Pfizer saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 54,661,544 shares, an increase of 5.2% from the July 13th total of 57,638,413 shares. Based on an average trading volume of 20,733,428 shares, the short-interest ratio is currently 2.6 days. Currently, 0.9% of the company's shares are short sold. View Pfizer's Current Options Chain. Who are some of Pfizer's key competitors? Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG). Who are Pfizer's key executives? Pfizer's management team includes the folowing people: Mr. Ian C. Read, Chairman & CEO (Age 64)Mr. Frank A. D'Amelio, Exec. VP of Bus. Operations & CFO (Age 60)Mr. Albert Bourla D.V.M., DVM, Ph.D., COO & Director (Age 56)Dr. Mikael Dolsten, Pres of Worldwide R&D (Age 59)Mr. John D. Young, Group Pres of Pfizer Innovative Health (Age 53) Has Pfizer been receiving favorable news coverage? News stories about PFE stock have been trending somewhat positive this week, according to Accern. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pfizer earned a news and rumor sentiment score of 0.09 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 46.48 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for Pfizer. Who are Pfizer's major shareholders? Pfizer's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.65%), Bank of New York Mellon Corp (1.14%), Massachusetts Financial Services Co. MA (1.04%), Morgan Stanley (0.91%), Dimensional Fund Advisors LP (0.91%) and Fisher Asset Management LLC (0.66%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Institutional Ownership Trends for Pfizer. Which institutional investors are selling Pfizer stock? PFE stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Russell Investments Group Ltd., Bank of New York Mellon Corp, Public Employees Retirement Association of Colorado, Legal & General Group Plc, Advisors Asset Management Inc. and American Century Companies Inc.. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Insider Buying and Selling for Pfizer. Which institutional investors are buying Pfizer stock? PFE stock was acquired by a variety of institutional investors in the last quarter, including Charles Schwab Investment Advisory Inc., Dimensional Fund Advisors LP, Macquarie Group Ltd., Federated Investors Inc. PA, Jensen Investment Management Inc., Natixis, Fisher Asset Management LLC and Unigestion Holding SA. View Insider Buying and Selling for Pfizer. How do I buy shares of Pfizer? Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Pfizer's stock price today? One share of PFE stock can currently be purchased for approximately $42.09. How big of a company is Pfizer? Pfizer has a market capitalization of $243.65 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $2.65 on an earnings per share basis. Pfizer employs 90,200 workers across the globe. How can I contact Pfizer? Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323. MarketBeat Community Rating for Pfizer (NYSE PFE)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 1,095 (Vote Outperform)Underperform Votes: 606 (Vote Underperform)Total Votes: 1,701MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/19/2018 by MarketBeat.com StaffFeatured Article: What is the NASDAQ Stock Market?